挑战施贵宝?康方生物PD-1/CTLA-4双抗在美国获孤儿药资格认定

读懂财经
25 Feb 2021

原标题:挑战施贵宝?康方生物PD-1/CTLA-4双抗在美国获孤儿药资格认定 来源:读懂财经2月23日,康方生物发布公告表示,公司产品Cadonilimab获美国FDA授予孤儿药资格认定,用于治疗宫颈癌适应症(除极早期IA1期之外)。Cadonilimab是一种PD-1/CTLA-4双抗,可同时靶向PD-1和CTLA-4靶点。PD-1是肿瘤细胞“逃逸”的重要信号通路,位于T细胞表面;CTLA-4是...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10